LifeArc CEO: UK Charity Is Cashing In Its Keytruda ‘Jackpot’ To Expand R&D Focus

 
• By Sten Stovall
  
Gambling
LifeArc hit the jackpot co-developing Merck & Co's PD-1 inhibitor Keytruda • Source: Shutterstock

More from Deals

More from Business